Eupraxia Pharmaceuticals (EPRX) Profit After Tax (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Profit After Tax data on file, last reported at -$12.7 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 87.0% year-over-year to -$12.7 million in Q1 2026; TTM through Mar 2026 was -$88.3 million, a 512.48% decrease from a year earlier, with the FY2025 full-year figure at -$38.6 million, down 48.9% from the prior year.
• Profit After Tax for Q1 2026 stood at -$12.7 million, up from -$60.5 million in the prior quarter.
• Over the last five years, Profit After Tax for EPRX reached as high as $6.1 million in Q2 2024 and fell as low as -$60.5 million in Q4 2025.
• Historically, Profit After Tax has averaged -$12.2 million across 4 years, with a median of -$6.6 million in 2025.
• Across the five-year window, Profit After Tax soared 83.43% in 2024 and slumped 683.96% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$46.6 million in 2023, then surged by 83.43% to -$7.7 million in 2024, then slumped by 683.96% to -$60.5 million in 2025, then jumped by 79.08% to -$12.7 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$12.7 million in Q1 2026, -$60.5 million in Q4 2025, and -$6.4 million in Q3 2025.